Founders: Daniel Nadler (CEO), Zack Ziegler
Launched: 2021
Headquarters: Miami, Florida
Funding: $795.4 million
Valuation: $12 billion
Key Technologies: Artificial intelligence
Industry: Health care
Previous appearances on Disruptor 50 list: 0
OpenEvidence has a narrow but powerful business idea: A large language model based on high-quality medical evidence.
The company, founded just five years ago, estimates that 40% of U.S. doctors use its tool daily and says it counts 10,000 medical centers as clients. It has content agreements with the Journal of the American Medical Association (JAMA) Network and the New England Journal of Medicine, among others.
Medical professionals can ask the AI model questions about things like dosing, treatment, or for evidence reviews. It produces information, including citations to peer-reviewed studies. It offers aid with more mundane tasks, including patient handouts and prior authorization letters.
Researchers have questioned AI models' accuracy, especially for complex medical scenarios, but investors are betting heavily on OpenEvidence's strategy, which includes two levels of inquiry, a search-engine-like Q&A, and a Deep Consult mode that generates research reports, rolled out in mid-2025.
Founder Daniel Nadler previously founded Kensho Technologies, an AI analytics startup acquired by S&P Global in 2018 for about $550 million. He joined with Harvard researcher Zachary Ziegler to start Miami-based OpenEvidence. In January, the company raised $250 million from investors, doubling its valuation to $12 billion. In less than a year, OpenEvidence raised $700 million from investors including Google's venture arm, Nvidia, Kleiner Perkins, David Sacks' Craft Ventures, Thrive Capital, DST, Sequoia, and Mayo Clinic.
"'ChatGPT for doctors' is a useful shorthand, but what we really do is help physicians make high-stakes clinical decisions at the point of care," Nadler told CNBC at the time of the most recent fundraise. "It's not trained on the open internet or social media, which can introduce low-quality medical information."
The company is flush, but faces stiff competition, from companies like Abridge, a fellow Disruptor, which operate in the space with competing AI models, and AI giants such as Anthropic, OpenAI, and Microsoft, which have products aimed at the medical profession.
Nadler does not see the competition as an all-or-nothing battle. "Healthcare is the largest segment of the real economy," he told CNBC. "People realize there could be a lot of winners in the space."
Sign up for our weekly, original newsletter that goes beyond the annual Disruptor 50 list, offering a closer look at the most promising venture-backed companies.
